Adoptive transfer (AT) T-cell therapy provides significant clinical benefits in patients with advanced melanoma. However, approaches to non-invasively visualize the persistence of transferred T cells are lacking. We examined whether positron emission tomography (PET) can monitor the distribution of self-antigen-specific T cells engineered to express an herpes simplex virus 1 thymidine kinase (sr39tk) PET reporter gene. Micro-PET imaging using the sr39tk-specific substrate 9-[4-[18F]fluoro-3-(hydroxymethyl)-butyl]guanine ([18F]FHBG) enabled the detection of transplanted T cells in secondary lymphoid organs of recipient mice over a 3-week period. Tumor responses could be predicted as early as 3 days following AT when a>25-fold increase of ...
Compelling evidence points to immune cell infiltration as a critical component of successful immunot...
For the past several decades, chimeric antigen receptor T-cell therapies have shown promise in the t...
Abstract Determination of treatment response to immunotherapy in glioblastoma multiforme (GBM) is a ...
Adoptive transfer (AT) T-cell therapy provides significant clinical benefits in patients with advanc...
Adoptive transfer (AT) T-cell therapy provides significant clinical benefits in patients with advanc...
Multiple diseases including blood disorders, autoimmunity, infections, and cancer result from defect...
Progress in understanding tumor-specific immune responses, genetic engineering and ex vivo manufactu...
A major barrier to successful use of allogeneic hematopoietic cell transplantation is acute graft-ve...
A general hindrance to progress in adoptive cellular therapy is the lack of detailed knowledge of th...
Positron emission tomography (PET) is a powerful noninvasive imaging technique able to measure disti...
In order for cellular therapeutics to succeed, comprehensive monitoring of the transplanted cells in...
Adoptive transfer of tumor-reactive T cells can successfully reduce tumor burden; however, in rare c...
High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using CD8+ ...
Adoptive transfer therapy of in vitro-expanded tumor-specific cytolytic T lymphocytes (CTLs) can med...
AbstractFor the past several decades, chimeric antigen receptor T cell (CAR T) therapies have shown ...
Compelling evidence points to immune cell infiltration as a critical component of successful immunot...
For the past several decades, chimeric antigen receptor T-cell therapies have shown promise in the t...
Abstract Determination of treatment response to immunotherapy in glioblastoma multiforme (GBM) is a ...
Adoptive transfer (AT) T-cell therapy provides significant clinical benefits in patients with advanc...
Adoptive transfer (AT) T-cell therapy provides significant clinical benefits in patients with advanc...
Multiple diseases including blood disorders, autoimmunity, infections, and cancer result from defect...
Progress in understanding tumor-specific immune responses, genetic engineering and ex vivo manufactu...
A major barrier to successful use of allogeneic hematopoietic cell transplantation is acute graft-ve...
A general hindrance to progress in adoptive cellular therapy is the lack of detailed knowledge of th...
Positron emission tomography (PET) is a powerful noninvasive imaging technique able to measure disti...
In order for cellular therapeutics to succeed, comprehensive monitoring of the transplanted cells in...
Adoptive transfer of tumor-reactive T cells can successfully reduce tumor burden; however, in rare c...
High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy using CD8+ ...
Adoptive transfer therapy of in vitro-expanded tumor-specific cytolytic T lymphocytes (CTLs) can med...
AbstractFor the past several decades, chimeric antigen receptor T cell (CAR T) therapies have shown ...
Compelling evidence points to immune cell infiltration as a critical component of successful immunot...
For the past several decades, chimeric antigen receptor T-cell therapies have shown promise in the t...
Abstract Determination of treatment response to immunotherapy in glioblastoma multiforme (GBM) is a ...